NCT04785989
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 21 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 23 words
- Primary and study completion pushed from Oct 2026 to Apr 2027
- Minor Site contact updatedv23
- Notable Primary and study completion dates: Oct 2025 to Oct 2026v22
- Notable Primary and study completion dates: Oct 2024 to Oct 2025v20
- Notable Phase: Not applicable to Not specifiedv19
Show 15 earlier versionsHide 15 earlier versions
- Notable Phase: Early Phase 1 to Not applicablev18
- Minor Start date changed from estimate of Jun 2022 to Jun 13, 2022v16
- Minor Start date: May 2022 to Jun 2022v15
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Minor Start date: Apr 2022 to May 2022v13
- Minor Start date: Mar 2022 to Apr 2022v11
- Minor Start date: Jan 2022 to Mar 2022v10
- Minor Start date: Dec 2021 to Jan 2022v9
- Minor Start date: Nov 2021 to Dec 2021v8
- Minor Start date: Oct 2021 to Nov 2021v7
- Notable Start date: Aug 2021 to Oct 2021v6
- Notable Start date: Jun 2021 to Aug 2021v5
- Minor Start date: May 2021 to Jun 2021v4
- Minor Start date: Apr 2021 to May 2021v3
- Minor Start date: Mar 2021 to Apr 2021v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysis
Timeframe: up to 2 hours (± 5 minutes)
Amount of [U-13C15N]L-glutamine incorporation into metabolites in normal and leukemic lymphocytes: LCMS pharmacokinetic analysis
Timeframe: up to 2 hours (± 5 minutes)
Arms and interventions
Group A: Healthy volunteers
Healthy volunteers are defined as people without a history of cancer
Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden
Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
Group B subset-2: Treatment naïve CLL patients with low disease burden
Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
Group C:Treatment naïve CLL patients with high systemic disease burden
Treatment naïve CLL patients with high systemic disease burden
Other: [U-13C]glucose, [13C5]glutamine
Sites
1 site in 1 country
- University of WisconsinMadison, Wisconsin, United States